A
Arthex Biotech
Focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs
About Arthex Biotech
Developer of anti-microRNAs designed for the treatment of diseases with unmet needs. The company develops drugs and therapies that are designed to treat a variety of disorders in which microRNAs play a role, enabling medical professionals to get access to therapy that helps treat patients suffering from genetic diseases, rare diseases, and diseases with high medical needs. Keywords: Pharmaceuticals and Biotechnology, Antisense Oligonucleotide, Antisense Oligonucleotide Therapy, Muscular Dystrophy, Neuromuscular Disease, Neuromuscular Disease Therapeutics, Neuromuscular Disease Treatment, Neuromuscular Therapy, Oligonucleotide Therapeutics, Oligonucleotide Therapy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Paterna, Spain
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 76.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Research and Development, Genetics and genomics, RNA, Spinout, Genome Engineering, EIC, Headstart (EIT Health), Headstart 2020 (EIT Health)
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2025 | $81M | $325M | CDTI · Columbus Venture Partners · AdBio partners · Sound Bioventures | ↗ |
| EARLY VCOther financing | May 2023 | $46M | $185M | Hadean Ventures · Sound Bioventures · EIC Fund · Columbus Venture Partners | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Arthex Biotech is 1.9K monthly website visits, up 18.8% over the last three months. Arthex Biotech's team grew 3.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
EIT Health
"la Caixa" Foundation
Invivo Partners
InVivo
AdBio partners
CDTI Innvierte
European Innovation Council
Series A6 investors entered at this stage
EIC Fund
Columbus Venture Partners
Hadean Ventures
Sound Bioventures
Bpifrance
CDTI
Series B and later1 investor entered at this stage
European Investment Bank
Other known investors1 additional known investor
University of Valencia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Arthex Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Arthex Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.